CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 33 enrolled
Drug / intervention
Capecitabine +1 moredrug
Likely dose
Capecitabine 825 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00916578
NCT00916578Phase 2Completed
CompareCT.gov

A Phase II Study of Preoperative Capecitabine and Concomitant Radiation in Women With Advanced Inflammatory or Non-Inflammatory Breast Cancer

M.D. Anderson Cancer Center·interventional·Posted Jun 9, 2009·Updated Jul 26, 2018

In Brief

A Phase 2 clinical trial evaluating Radiation Therapy and Capecitabine for Breast Cancer. Completed, enrolled 33 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to find out if Xeloda® (capecitabine) and radiation therapy can help to control breast cancer that did not respond well to chemotherapy. The safety of this study treatment will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 9, 2009
Enrollment StartJun 5, 2009
Primary CompletionJun 6, 2017
TodayJul 2, 2026
Enrollment to primary: 8.0 yearsPosted 17.1 years ago

Interventions

Radiation Therapyradiation

50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.

Capecitabinedrug

During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.